PF-08046031
- Generic Name
- PF-08046031
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Malignant MelanomaMelanomaMetastatic MelanomaSolid Tumors
- Interventions
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 185
- Registration Number
- NCT06799533
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath